EIF4EBP1 Knockout DLD-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the DLD-1 human colorectal adenocarcinoma epithelial cell line. This product enables loss-of-function studies of EIF4EBP1 (4E-BP1), a critical translation repressor, within a genetically defined colorectal cancer background. The pooled population, generated through targeted gene disruption, preserves cellular heterogeneity and avoids clonal selection artifacts, making it suitable for robust bulk assays such as signaling pathway analysis and drug response profiling.
The parental DLD-1 cell line, derived from a Duke??s type C adenocarcinoma, carries well-characterized oncogenic mutations in KRAS (G13D) and inactivating mutations in tumor suppressors APC and TP53. These epithelial cells serve as a classic model for studying colorectal tumorigenesis, metastasis, and therapeutic resistance, particularly in the context of hyperactivated growth factor signaling and its convergence on the translational machinery.
EIF4EBP1 functions as a translational repressor by binding to eIF4E, thereby blocking its incorporation into the eIF4F complex and inhibiting cap-dependent translation of pro-proliferative and pro-survival mRNAs such as CCND1, MYC, VEGFA, and BCL2. Its activity is regulated by mTORC1-mediated phosphorylation: upon PI3K-Akt pathway activation via growth factors or insulin/IGF-1, TSC1/TSC2 inhibition leads to Rheb-dependent mTORC1 activation, which phosphorylates 4E-BP1 on multiple residues, promoting its release from eIF4E. Conversely, under nutrient or energy stress, AMPK restrains mTORC1, maintaining 4E-BP1 in a hypophosphorylated, active state. Additional interacting factors include the mTORC1 scaffold Raptor, the homologs 4E-BP2 and 4E-BP3, and the PP2A phosphatase, which can dephosphorylate 4E-BP1.
In the DLD-1 colorectal cancer context, the mTORC1/EIF4EBP1/eIF4E axis is frequently dysregulated due to oncogenic KRAS and PI3K pathway activation, which persistently relieve translational repression. EIF4EBP1 knockout in this background can clarify its role as a potential tumor suppressor or adaptive mediator, particularly in controlling proliferation, survival, and angiogenesis. The polyclonal knockout population is ideal for dissecting how loss of this translational checkpoint cooperates with existing APC and TP53 mutations to modulate drug sensitivity, metabolic rewiring, and tumor progression.
This model supports a wide array of applications, including phospho-signaling array and Western blot analysis (phospho-4E-BP1, phospho-S6K, phospho-Akt), RT-qPCR quantification of downstream transcripts, cap-dependent translation reporter assays, cell proliferation (MTT, colony formation), apoptosis (Annexin V), and migration/invasion (Transwell) assays. It is also applicable to in vivo xenograft tumorigenesis studies and drug sensitivity testing with mTOR inhibitors such as rapamycin and everolimus. Global translational profiling via RNA-seq or polysome fractionation can complement targeted assays. For technical guidance or custom experimental design, please contact Ascent Research.
